active: true
address:
    address1: 3160 PORTER DR.
    address2: SUITE 250
    city: PALO ALTO
    postal_code: '94304'
    state: CA
branding:
    icon_url: https://api.polygon.io/v1/reference/company-branding/YnJpZGdlYmlvLmNvbQ/images/2025-04-04_icon.png
    logo_url: https://api.polygon.io/v1/reference/company-branding/YnJpZGdlYmlvLmNvbQ/images/2025-04-04_logo.png
cik: 0001743881
composite_figi: BBG00P9KDZK6
currency_name: usd
description: BridgeBio Pharma is a biotechnology company focused on discovering, developing,
    testing, and delivering transformative treatments for patients with genetic diseases.
    The company has four programs in its late-stage pipeline focusing on Mendelian
    disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis)
    , is an orally administered small molecule designed to stabilize tetrameric transthyretin
    for the treatment of transthyretin amyloid cardiomyopathy.
homepage_url: https://www.bridgebio.com
list_date: '2019-06-27'
locale: us
market: stocks
market_cap: 9631069231.52
name: BridgeBio Pharma, Inc. Common Stock
phone_number: (650) 391-9740
primary_exchange: XNAS
round_lot: 100
share_class_figi: BBG00P9KDZL5
share_class_shares_outstanding: 191168504
sic_code: '2834'
sic_description: PHARMACEUTICAL PREPARATIONS
ticker: BBIO
ticker_root: BBIO
total_employees: 730
type: CS
weighted_shares_outstanding: 191168504
